In This SectionTexas Health Research & Education Institute
Disease or Condition
Heart / Cardiac
A Phase 3, Randomized, Double Blind, Evaluation of the Safety and Efficacy of Apixaban in Subjects with a Recent Acute Coronary Syndrome (Heart/Cardiac)
This study will be looking to see if adding Apixaban (study drug), in addition to a patients' standard care, after an acute coronary syndrome event, is better than standard of care alone in preventing heart attacks, strokes, and other cardiac events.
Age 0-18 years.
Persistent severe hypertension (SBP = 180 mmHg or DBP = 110 mmHg)
Subjects who participated previously in any other study involving apixaban.
Severe comorbid condition with life expectancy of = 6 months.
Women who are pregnant, breastfeeding, or of childbearing potential and unwilling
or unable to use an acceptable method of birth control to avoid pregnancy.
Prisoners or subjects who are involuntarily incarcerated.